Observational studyBreast cancer (Tokyo, Japan)2022

Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.

Yuichiro Kikawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.